Protocol No.: KT-US-472-0141

Expanded access to commercially out-of-specification brexucabtagene autoleucel for the treatment of adult patients diagnosed with an FDA approved labeled indication
Principal Investigator
Safi, Salah Ud Din
Phase
NA
Age Group
Adult
Applicable Disease Sites
Leukemia
Lymphoma
Multiple Myeloma
Participating Institution
Mary Babb Randolph Cancer Center
Contact
Crystal Peck, RN
BMT Coordinator
Phone: +1 304-598-4500

View on ClinicalTrials.gov